Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)

Back to Search
Print
Bookmark Trial

NCT01441401

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Partial Epilepsies
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
3-15 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All the pediatric subjects (aged 3-15 years) whom an investigator prescribes the first gabapentin (tablets, syrup, and switch to syrup from tablet) should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients who have been enrolled in the drug use investigation of Gabapen tablets in
adults (protocol No. A9451163).


- Patients who receive Gabapen tablets or syrup before, except for switched from tablets
to syrup.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Partial EpilepsiesDrug Use Investigation Of Gabapentin
NCT00567268
ALL GENDERS
0+
years
MULTIPLE SITES
Partial EpilepsiesA Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
NCT00620555
  1. Obu-shi,Morioka-machi, Aichi
  2. Jonan-ku, Fukuoka
  3. Kobe, Hyogo
  4. Suma-Ku,Kobe, Hyogo
  5. Kanazawa, Ishikawa
  6. Zentsuuji, Kagawa
  7. Yokohama, Kanagawa Pref.
  8. Sendai-shi, Miyagi-ken
  9. Showa-Ku, Nagoya
  10. Niigata-shi, Niigata
  11. Kurashiki-City, Okayama Pref.
  12. Okayama-shi, Okayama
  13. Izumi-shi, Osaka
  14. Miyakojima-ku, Osaka
  15. Suita, Osaka
  16. Shizuoka-shi, Shizuoka
  17. Kodaira, Tokyo
  18. Setagaya-ku, Tokyo
  19. Shinjuku-ku, Tokyo
  20. Hiroshima,
  21. Saitama,
  22. Yamagata,
ALL GENDERS
3 Years+
years
MULTIPLE SITES
Partial EpilepsiesSafety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
NCT00437281
  1. Mobile, Alabama
  2. Mobile, Alabama
  3. Phoenix, Arizona
  4. Jonesboro, Arkansas
  5. Little Rock, Arkansas
  6. San Francisco, California
  7. Gulf Breeze, Florida
  8. Pensacola, Florida
  9. Tampa, Florida
  10. Tampa, Florida
  11. Springfield, Missouri
  12. Buffalo, New York
  13. Durham, North Carolina
  14. Houston, Texas
  15. San Antonio, Texas
  16. Seoul,
  17. Mexico, DF
  18. Guadalajara, Jalisco
ALL GENDERS
1 Month+
years
MULTIPLE SITES
Partial EpilepsiesSafety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)
NCT01441401
ALL GENDERS
3 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)
Official Title Special Investigation Of Gabapen For Pediatric (Regulatory Post Marketing Commitment Plan)
Brief Summary

This investigation aims to understand the following issues in pediatric patients, as well as to assess the need of a special investigation and a post-marketing clinical study:

  • The frequency of treatment related adverse events.
  • The frequency of efficacy assessment.
  • Treatment related unlisted adverse events in Japanese Package Insert.
  • Risk factors likely to affect the frequency of treatment related adverse event.
Detailed Description All the patients whom an investigator prescribes the first gabapentin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population The study whom an investigator involving A9451175 prescribes the Gabapentin
Condition Epilepsies, Partial
Intervention Drug: gabapentin
According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
Study Groups/Cohorts Gabapentin
Peadiatric subjects taking Gabapen Tablets and syrup.
Intervention: Drug: gabapentin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: August 3, 2015)		82
Original Estimated Enrollment
 (submitted: September 23, 2011)		300
Actual Study Completion Date September 2014
Actual Primary Completion Date August 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • All the pediatric subjects (aged 3-15 years) whom an investigator prescribes the first gabapentin (tablets, syrup, and switch to syrup from tablet) should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Exclusion Criteria:

  • Patients who have been enrolled in the drug use investigation of Gabapen tablets in adults (protocol No. A9451163).
  • Patients who receive Gabapen tablets or syrup before, except for switched from tablets to syrup.
Sex/Gender
Sexes Eligible for Study:All
Ages 3 Years to 15 Years   (Child)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01441401
Other Study ID Numbers A9451175
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date August 2016